UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1084-13
Program Prior Authorization/Notification
Medication Pulmozyme® (dornase alfa)
P&T Approval Date 8/2012, 5/2013, 2/2014, 2/2015, 2/2016, 2/2017, 2/2018, 2/2019,
2/2020, 2/2021, 2/2022, 2/2023, 2/2024, 2/2025
Effective Date 5/1/2025
1. Background:
Pulmozyme (dornase alfa) is a recombinant deoxyribonuclease (DNase) enzyme indicated in
conjunction with standard therapies for the management of cystic fibrosis (CF) patients to
improve pulmonary function.
In CF patients with a forced vital capacity (FVC) ≥ 40% of predicted, daily administration of
Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring
parenteral antibiotics.1
Members will be requi red to meet the coverage criteria below.
2. Coverage Criteriaa:
A. Initial Authorization
1. Pulmozyme will be approved based on both of the following criteria:
a. Diagnosis of cystic fibrosis
-AND-
b. Used in conjunction with standard CF therapies [e.g., chest physiotherapy,
bronchodilators, antibiotics, anti-inflammatory therapy (e.g., ibuprofen, oral/inhaled
corticosteroids)]
Authorization of therapy will be issued for 12 months.
B. Reauthorization
1. Pulmozyme will be approved based on the following criterion:
a. Documentation of positive clinical response to Pulmozyme therapy
Authorization will be issued for 12 months
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
© 2025 UnitedHealthcare Services, Inc.
1
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-
10) and/or claim logic. Use of automated approval and re-approval processes varies by
program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Pulmozyme [package insert]. South San Francisco, CA: Genentech, Inc.; July 2021.
2. Mogayzel P, Naureckas E, Robinson K, Mueller G, Hadjiliadis D, Hoag J, Lubsch L,
Hazle L, Sabadosa K, Marshall B; Cystic fibrosis pulmonary guidelines. Chronic
medications for maintenance of lung health. American Journal of Respiratory and Critical
Care Medicine 2013;187:680-689.
Program Prior Authorization/Notification - Pulmozyme (dornase alfa)
Change Control
2/2014 Updated authorization to 60 months. Removed reauthorization criteria.
2/2015 Annual review with no change to coverage criteria. Updated references.
2/2016 Annual review with no changes to clinical content. Changed
authorization period to 12 months and added re-authorization period for
12 months. Administrative changes only to background section.
Updated reference.
2/2017 Annual review with no changes to coverage criteria.
2/2018 Annual review with no changes to coverage criteria.
2/2019 Annual review. Updated references. Updated background information.
2/2020 Annual review. Updated background. No changes to coverage criteria.
2/2021 Annual review. No changes to coverage criteria.
2/2022 Annual review with no changes to coverage criteria. Updated
references.
2/2023 Annual review. No changes to coverage criteria. Added state mandate
footnote.
2/2024 Annual review with no changes to coverage criteria.
2/2025 Annual review with no changes to coverage criteria.
© 2025 UnitedHealthcare Services, Inc.
2